GILD250117C67500
- 24.87
- 0.000.00%
Gilead Sciences Newsroom
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences Hits 4-week High
Goldman Sachs Adjusts Price Target on Gilead Sciences to $85 From $84, Keeps Neutral Rating
These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Safely
Wells Fargo Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Optimistic Buy Rating for Gilead Sciences: Anticipated EPS Growth and Strong Performance in 2024
GILD Vs. ALNY: Which Stock Is the Better Value Option?
RBC Capital Remains a Hold on Gilead Sciences (GILD)
Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Outset Medical (OM)
Express News | Gilead : RBC Raises Target Price to $84 From $83
Why Gilead Sciences (GILD) Outpaced the Stock Market Today
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
8 Health Care Stocks Whale Activity In Today's Session
Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others
Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?
"Seladelpar Approved To Treat Adult Patients In The UK With Liver Illness; As With Any Medicine, The MHRA Will Keep The Safety And Effectiveness Of Seladelpar Under Close Review" - UK Gov
Express News | UK's Mhra: Seladelpar Approved to Treat Adult Patients in UK With Liver Illness - Website
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $115
Gilead Sciences: Strategic Growth and Optimism Amidst Market Challenges